21-Gene Assay Associated with Significant Change in Treatment Decisions
the Cancer Therapy Advisor take:
Physicians were more likely to change treatment decisions after evaluating patients using the 21-gene Oncotype DX Assay, according to an article published online in the journal The Oncologist.
Ninety-five patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative early-stage breast cancer (ECB), and node-negative (pN0) disease or micrometastases in up to three lymph nodes (pN1mi) were evaluated regarding their cancer treatments.
Results showed that treatment regimen recommendations changed in 37% of patients, primarily from chemoendocrine to strictly endocrine treatment. The proportion of patients recommended to undergo chemotherapy treatment was also found to decrease from pretest to post-test (52% to 25%, respectively).
After receiving the Oncotype Recurrence Score result, 61% of patients who were originally recommended chemotherapy treatment were newly advised to receive endocrine treatment alone.
Furthermore, physicians’ confidence significantly improved after receiving the Recurrence Score value.
The authors noted that Oncotype DX testing is associated with an overall reduction in chemotherapy use as treatment in patients with ER+, human epidermal growth factor receptor 2-negative EBC, which was consistent with previous studies.
Physicians were more likely to change treatment decisions after evaluating patients using the 21-gene Oncotype DX Assay.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia